according to the Globally Harmonized System



Bezlotoxumab Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 1.18
 28.09.2024
 818321-00019
 Date of first issue: 22.07.2016

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Bezlotoxumab Formulation

Manufacturer or supplier's details

Company : MSD

Address : Briahnager - Off Pune Nagar Road

Wagholi - Pune - India 412 207

Telephone : +1-908-740-4000

Emergency telephone number : +1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification

Not a hazardous substance or mixture.

GHS label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

Other hazards which do not result in classification

None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (%
		w/w)
Bezlotoxumab	1246264-45-8	>= 1 - < 5

4. FIRST AID MEASURES

according to the Globally Harmonized System



Bezlotoxumab Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023
1.18 28.09.2024 818321-00019 Date of first issue: 22.07.2016

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap as a precaution.

Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

None known.

Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms

delayed

and effects, both acute and

Protection of first-aiders : No special precautions are necessary for first aid responders. Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- :

ucts

Carbon oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for firefighters

Wear self-contained breathing apparatus for firefighting if nec-

essary.

Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

parriers)

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

according to the Globally Harmonized System



Bezlotoxumab Formulation

Revision Date: SDS Number: Version Date of last issue: 30.09.2023 1.18 28.09.2024 818321-00019 Date of first issue: 22.07.2016

cannot be contained.

Methods and materials for containment and cleaning up Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

7. HANDLING AND STORAGE

Technical measures See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation

Use only with adequate ventilation.

Advice on safe handling Handle in accordance with good industrial hygiene and safety

practice, based on the results of the workplace exposure as-

sessment

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage

Keep in properly labelled containers.

Store in accordance with the particular national regulations.

Materials to avoid Do not store with the following product types:

Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Bezlotoxumab	1246264-45- 8	TWA	5.0 mg/m3 (OEB 1)	Internal

Engineering measures Use appropriate engineering controls and manufacturing

technologies to control airborne concentrations (e.g., drip-less

quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Laboratory operations do not require special containment.

Personal protective equipment

Respiratory protection If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

according to the Globally Harmonized System



Bezlotoxumab Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 1.18
 28.09.2024
 818321-00019
 Date of first issue: 22.07.2016

ommended guidelines, use respiratory protection.

Filter type
Hand protection

: Particulates type

Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Aqueous solution

Colour : Colorless to pale yellow

Odour : No data available

Odour Threshold : No data available

pH : 5.7 - 6.3

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

according to the Globally Harmonized System



Bezlotoxumab Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 1.18
 28.09.2024
 818321-00019
 Date of first issue: 22.07.2016

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : 1.0146 g/cm³

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, dynamic : 1.2 mPa.s (25 °C)

Viscosity, kinematic : 1.833 mm2/s (4 °C)

1.183 mm2/s (25 °C)

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : Not applicable

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac- :

tions

Stable under normal conditions.

Can react with strong oxidizing agents.

Conditions to avoid : None known. Incompatible materials : Oxidizing agents

Hazardous decomposition : No hazardous decomposition products are known.

products

11. TOXICOLOGICAL INFORMATION

Information on likely routes of:

exposure

Inhalation
Skin contact
Ingestion

Eye contact

Acute toxicity

Not classified based on available information.

according to the Globally Harmonized System



Bezlotoxumab Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 1.18
 28.09.2024
 818321-00019
 Date of first issue: 22.07.2016

Components:

Bezlotoxumab:

Acute toxicity (other routes of : LD50 (Mouse): > 125 mg/kg

administration) Application Route: Intravenous

Remarks: No adverse effect has been observed in acute tox-

icity tests.

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Not classified based on available information.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

Bezlotoxumab:

Species : Mouse
NOAEL : 50 mg/kg
Application Route : Intravenous

Exposure time : 15 d

Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 125 mg/kg
Application Route : Intravenous

Exposure time : 21 d

Remarks : No significant adverse effects were reported

according to the Globally Harmonized System



Bezlotoxumab Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 1.18
 28.09.2024
 818321-00019
 Date of first issue: 22.07.2016

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Bezlotoxumab:

Inhalation : Symptoms: Nausea, Headache, Diarrhoea, Fever

12. ECOLOGICAL INFORMATION

Ecotoxicity

No data available

Persistence and degradability

No data available

Bioaccumulative potential

No data available

Mobility in soil

No data available

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

Not applicable

according to the Globally Harmonized System



Bezlotoxumab Formulation

Date of last issue: 30.09.2023 Version Revision Date: SDS Number: 1.18 28.09.2024 818321-00019 Date of first issue: 22.07.2016

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

cy, http://echa.europa.eu/

Internal technical data, data from raw material SDSs, OECD

eChem Portal search results and European Chemicals Agen-

The components of this product are reported in the following inventories:

AICS not determined

DSL not determined

IECSC not determined

16. OTHER INFORMATION

28.09.2024 **Revision Date**

Further information

Sources of key data used to

compile the Safety Data Sheet

Date format dd.mm.yyyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China: IMDG - International Maritime Dangerous Goods: IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Sub-

according to the Globally Harmonized System



Bezlotoxumab Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 1.18
 28.09.2024
 818321-00019
 Date of first issue: 22.07.2016

stances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN